

IMPACT OF HELICOBACTER PYLORI ON PROGNOSIS OF PATIENTS WITH ACUTE CORONARY SYNDROME

Rahime Eskandarian MD, Shahrokh Moosavi MD, Mehdi Babai MD, Jafar Toussy MD
Raheb Ghorbani MD, Mojtaba Malek MD, Mohsen Shiasi MD, Behroz Momeni MD
Ali Ghasemi MD, Azade Vatani MD, Mehrdad Zahmatkesh BS

Abstract

INTRODUCTION: Coronary artery disease (CAD) is the main cause of mortality in industrial and developing countries. New risk factors including infections are under investigation as potential factors. One of these infectious agents is *Helicobacter pylori*, which has been investigated in numerous studies. This study was designed in view of the controversies surrounding the impact of *Helicobacter pylori* on the prognosis of patients with acute coronary syndrome (ACS).

METHODS: All patients with ACS including unstable angina and myocardial infarction who were referred to Fatemeh Hospital between 20 February 2003 and 19 February 2004 and were admitted to the CCU ward were enrolled in this cohort study. A total of 411 patients with ACS were evaluated for *Helicobacter pylori* serologically, and the occurrence of cardiac events needing angioplasty or coronary surgery was assessed.

RESULTS: Mean age of patients was 59.97 ± 38.12 years and 56% of them were male. The serology test for *Helicobacter pylori* infection was positive in $45.6 \pm 12.38\%$, negative in 43.8%, and borderline in 10.6% of patients. 191 patients had unstable angina and 220 patients had myocardial infarction. In a one-month follow-up, 10% of the patients developed cardiac events and PCI or CABG was performed in 6.1% (16.1% totally). One-month occurrence of cardiac events in the group with *Helicobacter pylori* infection was 11.9% vs. 19.3% in the group without infection ($\chi^2 = 3.078$, $P = 0.079$).

DISCUSSION: This prospective study showed that *Helicobacter pylori* infection has no effect on short term prognosis of patients with ACS.

Keywords • *Helicobacter pylori* • Acute coronary syndrome • Prognosis

ARYA Journal, 2005, 1(3): 164-169

Introduction

Coronary artery disease (CAD) is the main cause of mortality in industrial and developing countries.^{1,2}

Several risk factors such as cigarette smoking, hypertension, hyperlipidemia and diabetes have been proposed.^{3,4} In some patients, no risk factor is found. These patients should be investigated for other risk factors such as infections.

Infectious agents like Chlamydia pneumonia, Cytomegalovirus, Herpes simplex and *Helicobacter pylori* (*H. pylori*) may have a probable role,^{5,9} but no definitive cause and effect correlation between these agents and unstable angina (UA) or myocardial infarction (MI) has yet been approved.^{10,11}

The role of Chlamydia pneumonia as a potentially important and treatable cause for UA or MI is under investigation.¹²⁻¹⁶

Many researchers have probed the role of *H. pylori* as a potential risk factor for CAD¹⁷⁻²⁰ and some studies have pointed to an association between *H. pylori* and CAD.^{3,6,7,16,23-30} After modification of other cardiac risk factors in some studies, the role of *H. pylori*

corresponding author

Rahime Eskandarian, Internal Medicine Research Center,
Fatemeh Hospital, 17th Shahrivar Blvd, Semnan, Iran
Tel: +98-231-3341449; Fax: 3328302
Email: rheskandarian@yahoo.com

in the development of CAD weakened or disappeared.^{5,32-34} A number of studies have ruled out H. pylori as a risk factor for coronary disease.³⁵⁻³⁸ In some studies, the rate of positive serology tests for H. pylori has been greater in the control group.³⁶ Although H. pylori has been proposed as a probable cause of coronary disease in reference books,^{3,5} much doubt remains.

Numerous studies have been conducted about the impact of H. pylori on the prognosis of patients with coronary artery disease.

In one study, MI or mortality rate in one-year follow-up in patients with H. pylori was 22% vs. 18% in normal persons (P=0.1).³⁸

Another study measured six inflammatory factors, anti-chlamydia antibody, anti-cytomegalovirus antibody and anti-H. pylori antibody in patients with UA, as well as in controls.

In this study, one-year prognosis, as determined by such events as recurrent angina, MI, need for angioplasty, coronary surgery, and sudden death had no correlation with positive serologic results.¹⁰ In another study, recurrence of acute coronary syndrome and sudden death apparently diminished in patients with history of MI or UA who had positive serology tests and were treated with erythromycin and roxytromycin.¹⁵

This study was designed in view of the controversies surrounding increased cardiac events in ACS in patients with positive serology tests for H. pylori.

Materials and methods

This is a cohort study of patients with acute coronary syndrome (UA or MI) admitted to CCU of Fatemeh Hospital, Semnan, Iran, between 20 Feb 2003 and 19 Feb 2004. Written informed consent was obtained from all patients. A questionnaire obtaining demographic data, type of ACS, main risk factors (hypertension, hyperlipidemia, cigarette smoking and family history of ischemic heart disease) was completed by each patient. Within the first 48 hours of admission, a blood sample (5 cc) was taken and centrifuged to assess IgA (marker of acute H. pylori infection) and IgG (marker of chronic H. pylori infection). We used Dialups kits to measure IgA; IgG was measured with ELISA. IgA or IgG levels greater than 30, between 15 and 30, and below 15 were considered as positive, borderline, and negative, respectively. Patients were followed for a month, and recurrent angina, MI, sudden death, PCI and CABG were evaluated in them.

Diagnosis of UA and MI was based on history, physical exam, EKG and cardiac enzymes (CPK, CK-MB and troponin). After sample collection, obtained data were analyzed using SPSS (v. 11.5) software with χ^2 and analytic regression tests (alpha=0.05).




FIGURE 1. Prevalence of major risk factors of ischemic heart disease in patients with unstable angina and myocardial infarction

TABLE 1. Incidence of cardiac within one month of admission

Type of event	Prevalence	Percent	Total (%)
Unstable angina	34	8.3	51.5
Myocardial infarction	6	1.5	9.1
Sudden death	1	0.2	1.5
Angioplasty	13	3.2	19.7
CABG	12	2.9	18.2
total	66	16.1	100

TABLE 2. Association between cardiac events and serology of Helicobacter pylori

		One-month evaluation		Total
		Negative	Positive	
Anti H. pylori antibody (IgA or IgG)	Negative	117 80.7	28 19.3	145 100%
	Positive	133 88.1	18 11.9	151 100%
Total		250 84.5%	46 15.5%	296 100%

Results

A total of 411 patients were studied. Mean age of subjects was 59.97 ± 38.12 years and 56% were male. The serology test for H. pylori infection was positive in $45.6 \pm 12.38\%$, negative in 43.8% and borderline in 10.6% of patients. The two groups of patients were not significantly different in terms of the main coronary risk factors ($P > 0.05$). 191 patients had UA and 220 patients had MI.

Figure 1 shows the main coronary risk factors in the two groups. In a one-month follow-up, 10% of the patients were involved in cardiac events. PCI or CABG was performed in 6.1% of the patients (16.1% of total) (Table 1).

There was no correlation between H. pylori infection and main coronary risk factors (hypertension, hyperlipidemia, diabetes and cigarette smoking) ($P > 0.05$). Besides, these risk factors had no significant correlation with one-month cardiac events ($P > 0.05$). In the H. pylori infected group, the one-month incidence of cardiac events was 11.9% vs. 19.3% in the non-infected group ($\chi^2 = 3.078$, $P = 0.079$) (Table 2).

Discussion

Several studies have shown that inflammation is involved in the formation and progression of atherosclerosis. H. pylori is a known cause of inflammation. Both CAD and H. pylori infection are prevalent in the population and are closely associated with socioeconomic status.³⁷ On the other hand, if the correlation of H. pylori and CAD with the

prognosis of patients is verified, the treatment of this infection would likely reduce the incidence of CAD and its related cardiovascular events.³⁷ Since H. pylori is acquired during childhood, development of a vaccine for children might be considered.³⁷

H. pylori, which is colonized from childhood years may be in close association with CAD.^{1,3-5,7} But recent studies have shown a weak association, or no association between H. pylori and CAD.^{5,32-38}

In a large-scale study, patients were followed for 13 years and were examined at 5-year intervals. Mean follow-up period was 13.7 years. This study did not show any clear association between serology test positive for H. pylori and the incidence of CAD (at the start or during the study), but there was an apparent correlation between H. pylori infection and the risk of fatal CAD (OR=1.54, CI 95%: 1.30-2.30). Thus after heart attack, the ratio of patients with positive serology test who died was higher than that of patients with negative serology test (57% vs. 45%, OR=2, CI 95%: 1.19-3.36).⁴⁰ In another study, six inflammatory factors and serologic markers of Chlamydia pneumonia, Cytomegalovirus and Helicobacter pylori were measured in patients with history of acute coronary syndrome. There was no association between level of inflammatory markers and serologic states. The percentage of cardiac events and the need for coronary revascularization in one year showed no difference based on serologic tests.¹⁰ However, antibiotic treatment can reduce future cardiac events in patient with acute coronary syndrome.

This effect is independent of positive serology for Chlamydia and *H. pylori*.¹⁵

In addition, an association has been shown between the number of infectious agents (such as Chlamydia, Hemophilus influenza, Epstein bar virus, Helicobacter pylori and Herpes simplex) and the extent of atherosclerosis and risk of future events.⁴¹

In the United States, the incidence of MI or death in patients with *H. pylori* was 22% vs. 18% in normal individuals ($P=0.1$).

The results of the above-mentioned studies are in concordance with our study.

Meanwhile, some studies resulted in controversial effects. The probability of coronary events was greater in patients who were not treated for *H. pylori*.⁴² During a 3-year follow-up, the incidence of recurrent MI and death was greater in patients with positive serology. The probability of adjusted risk for MI or death (related to positive *H. pylori* serology) was 1.12.³⁸ Two studies were conducted on the effects of erythromycin and roxithromycin on the incidence of acute coronary syndrome after MI or UA. Based on these surveys, the incidence of coronary disease had decreased significantly during subsequent follow-ups.¹⁶ In another study, prognosis of patients with *H. pylori* infection who were treated improved during the follow up period.⁴²

Consequently, in spite of the short follow-up period in our study, concordance of results was noted.^{10,15,40}

Mortality rate, recurrent angina or infarction, and the need for revascularization (PCI or CABG) showed no significant difference between the two groups.

Since no clear association has yet been shown between the prognosis of CAD and positive serology test, the difference between our results and those of other studies^{16,38,42} may originate from certain problems.

Interactions between chronic *H. pylori* infection and the coronary arteries which is mainly due to immunologic reactions, can change lipid metabolism and cause hypercholesterolemia and increase the risk of consequent atherosclerosis.

Therefore if confounding factors are not matched between the two groups, they can influence the prognosis. In studies with well-controlled confounding factors, positive serology of *H. pylori* had no association with prognosis.^{10,15,40} Type of diagnostic test for *H. pylori* infection can affect the results, hence that we assessed IgA and IgG as markers of acute and chronic infection in our study.

On the other hand, since these antibiotics have widespread antimicrobial effects, they probably

eliminate other germs such as the bacterial causes of chronic bronchitis, pyorrhea and even normal gastric flora, and may reduce cardiac events via this mechanism. Recent data point to the importance of the total amount of bacteria in the development of atherosclerosis.

Although improvement in the prognosis of acute coronary syndrome after antibiotic medication may be due to anti-inflammatory, anti-oxidant and anti-thrombotic effects of these drugs which reinforce and fix atherosclerotic plaques, further studies are needed to assess the long-term effects of shorter-term antibiotic treatments.

Acknowledgement

We extend our gratitude to Mr Amoozadeh and all the personnel of the Emergency Ward of Fatemeh Hospital for their cooperation with this study.

References

1. Hara K, Morita Y, Kamihata H, Iwasaka T, Takahashi H. Evidence for infection with Helicobacter pylori in patients with acute myocardial infarction. Clin Chim Acta 2001 Nov;313(1-2):87-94.
2. Pellicano R, Oliaro E, Mangiardi L, Orzan F, Bergerone S. Ischemic cardiovascular disease. Correlation with Helicobacter pylori infection. Minerva Cardioangiol 2000 Dec;48(12):467-73.
3. Libby P. Pathogenesis of atherosclerosis. Chapter 224 pp: 1425-1434, Christopher, Cannon, Eugene Braunwald; Unstable angina and non-ST elevation myocardial infarction. Chapter 227; pp: 1444-1448 HARRISON'S: Principles of INTERNAL MEDICINE 16th Edition (2005).
4. Wannamethee SG. Risk factors for stroke: overview, J Cardiovasc Risk, 1999,6(4):199-202.
5. BRAUNWALD ZIPES LIBBY: Heart Disease 6th Edition (2001),1006-31,1232 -8.
6. Rowland M, Drumm B. Helicobacter pylori and sudden infant death syndrome. Lancet 2001 Feb 3; 357(9253):327.
7. Fong IW. Emerging relations between infection disease and coronary artery disease and atherosclerosis. CMAJ, 2000,163 (1):49-56.
8. Colozzi C, Rizzello V, Angiolillo DJ, Liuzzo G, Ginnetti F, Manaco C et al. In vitro hyper reactivity to lipopolysaccharide in patients with history of unstable angina is not associated with seropositive for Cytomegalovirus, Helicobacter pylori and Chlamydia pneumoniae. Cardiologia 1999,44(4):377-80.
9. Wierzbicki WB, Hagemeyer KO. Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus:

- chronic infection and coronary heart disease. *Pharmacotherapy*, 2000,20(1):52-63.
10. Kerr JR. Sudden infant death syndrome, long QT interval, and *Helicobacter pylori*. *J Clin Pathol* 1998 Dec;51(12):943-4.
 11. Kerr JR, AL -Khattaf A, Barson AJ, Burnie JP. An association between Sudden infant death (SIDS) and *Helicobacter pylori* infection. *Arch Dis Child* 2000 Nov;83(5):429-34.
 12. Muhlestein JB. Bacterial infections and atherosclerosis. *J Investing Med* 1998 Oct;46(8):396-402.
 13. Pellicano R, Oliaro E, Rizzetto M, Ponzetto A. Infections and cardiovascular diseases in ischemic basis. The case of *Helicobacter pylori*. *Minerva Med* 2000 Jul-Aug;91(7-8):161-7.
 14. Martinez Torres A, Martinez Gaensly M. *Helicobacter pylori*: a new Cardiovascular risk factor? *Rev Esp Cardiol* 2002 Jun;55(6):652-6.
 15. Stone AF, Mendall MA, Kaski JC, Edger TM, Risley P, Polniecki J. Effect of treatment for *Chlamydia pneumoniae* and *Helicobacter pylori* on markers of inflammation and cardiac events in patients with acute coronary Syndromes: South Thames Trail of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). *Circulation* 2002 Sep 3;106(10):1219-23.
 16. Grabczewska Z, Nartowicz E. Infection with *Chlamydia pneumoniae*, *Helicobacter pylori* and Cytomegalovirus and atherosclerosis. *Przegl Lek*. 1999,56(9):584-7.
 17. Gammarota G, Pasceri V, Papa A, Cianci R, Gasbarrini A et al. *Helicobacter pylori* infection and ischemic heart disease. *Ital J Gastroenterol Hepatol* 1998 Oct;30(Suppl 3:5)304-6.
 18. Famularo G, Trinchieri V, Santini G, DeSimone C. Infection. Atherosclerosis and coronary heart disease. *Ann Ital Med Int*, 2000,15(2):144-55.
 19. Danesh J, Youngman L, Clark S, Parish S, Peto R, Collins R. *Helicobacter pylori* infection and early onset myocardial infection. *BMJ*, 1999,319(7218): 1157-62.
 20. Pasceri V, Cammarota G, Patti G, Cuoco L, Gasbarrini A, Grillo RL. et al. Association of virulent *Helicobacter pylori* strains with ischemic heart disease. *Circulation*. 1998,97(17):1675-9.
 21. Ammann P, Marschall S, Kraus M, Schmid L, Angehrn W, Krapf R, Rickli H. Characteristics and prognosis of myocardial infarction in patients with normal Coronary arteries. *Chest* 2000 Feb;117(2)333-8
 22. Murray LJ, Bamford KB, O'Reilly DP, McCrum EE, Evans AE. *Helicobacter pylori* infection: relation with cardiovascular risk factors, ischaemic heart disease, and social class. *Br Heart J* 1995 Nov; 74(5):497-501.
 23. Parente F, Bianchi Porro G. *Helicobacter pylori* infection and ischaemic heart disease: is there a link? *Ital J Gastroenterol Hepatol* 1998 Feb;30(1):119-23.
 24. Patel P, Mendall MA, Carrington D, Strachan DP, Leatham E, Molineaux N, Levy J, Blakes C, Seymour CA, Camm AJ. Association of *Helicobacter pylori* and chlamydia pneumonia infections with coronary disease and Cardiovascular risk factor. *BMJ* 1995 Sep 16;311(7007):711-4.
 25. Pellicano R, Parravicini PP, Bigi R, La Rovere MT, Baduini G, Gandolfo N. Patients with acute myocardial infarction in northern Italy are often infected by *Helicobacter pylori*. *Panminer va Med* 1999 Dec;41(4):279-82.
 26. Stone AF, Mendall MA. *Helicobacter pylori* is an etiological factor for ischaemic heart disease: the case in favor. *Dig Liver Dis* 2000 Jan-Feb;32(1):62-4.
 27. Laurila A, Bloigu A, Nayha S, Hassi J, Leinonen M, Saikku P. Association of *Helicobacter pylori* infection with elevated serum lipids, Atherosclerosis, 1999,142(1):207-10.
 28. Pieniazek P, Karczewska E, Duda A, Tracz W, Pasowicz M, Konrurek SJ. Association of *Helicobacter pylori* infection with coronary heart disease. *J Physiol Pharmacol*. 1999,50(5):743-51.
 29. Pilotto A, Rumor F, Franceschi M, Leandro G, Novello R, Soffiati G, et al. Lack of association between *Helicobacter pylori* infection and extracardial atherosclerosis in dyspeptic elderly subjects. *Age Aging*, 1999,28(4):367-71.
 30. Whincup P, Danesh J, Walker M, Lennon L, Thomson A, Appleby P et al. Prospective study of potentially virulent strains of *Helicobacter pylori* and coronary heart disease. *Circulation*, 2000,101(14): 1647-52.
 31. Tsai CJ, Huang TY. Relation of *Helicobacter pylori* infection and angiographically demonstrated coronary artery disease. *Dig Dia Sci*, 2000,45(6): 1227-32.
 32. Strachan DP. Non-gastrointestinal consequences of *Helicobacter pylori* infection. *Br Med Bull*, 1998, 54(1):87-93.
 33. Whincup PH, Mendall MA, Perry IJ, Strachan DP, Walker M. Prospective relations between

- Helicobacter pylori and coronary heart disease, and stroke in middle aged men, *Heart* 1996;75(6):568-72.
34. Roivvainen M, Viik-Kajander M, Palosuo T, Toivanen P, Leinonen M, Saikku P et al. Infections inflammation and the risk of coronary heart disease. *Circulation* 2000;101(3):252-7.
35. Choussat R, Montalescot G, Collet J, Ankri A, Fillet A, Thomas D, Raymond J, Bastord J, Drobinski G, Orfila J. Effect of prior exposure to Chlamydia pneumoniae, Helicobacter pylori or cytomegalovirus on the degree of inflammation and one-year Prognosis patients with unstable angina pectoris or non-Q-Wave acute myocardial infarction.' *Am J Cardiol* 2000 Aug 15; 86(4): 379-84.
36. Murray LJ, Bamford KB, Kee F, Mc Master D, Cambien F, Dallongeville J, Evans A. Infection with virulent strains of Helicobacter pylori is not associated with ischaemic heart disease: evidence from a population-based case-control study of myocardial infarction. *Atherosclerosis* 2000 Apr; 149 (2):379-85.
37. Rathbone B, Martin D, Stephens J, Thompson JR, Samani NJ. Helicobacter pylori seropositivity in subjects with acute myocardial infarction. *Heart* 1996 Oct;76(4):308-11
38. Zhu J, Quyyumi AA, Muhlestein B, Nieto FJ, Horne BD, Zalles-Ganley A, Anderson JL, Epstein SE. Lack of association of Helicobacter pylori infection with coronary artery disease and frequency of acute myocardial infarction or death. *Am J Cardiol* K Gordio 2000 Jan 15;89(2):155-5
39. De Koster E, De Bruyne I, Lanlet P, Deltenre M. Evidence-based medicine and extradigestive Manifestations of helicobacter pylori. *Acta Gastroenterol Belg* 2000 Oct-Dec; 63(4):388-92.
40. Strachan DP, Mendall MA, Carrington D, Butland BK, Yarnell JW, Sweetnam PM et al. Relation of helicobacter pylori infection to 13-year mortality and incident ischemic heart disease in the Caerphilly prospective heart disease. *Circulation* 1998 Sep 29;98(13):1286-90.
41. Klein C, Rupprecht H, Blankenberg S, Bickel C, Kopp H, Ripplin G et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. *Circulation* 2002;105(15):1-7.
42. Elizalde I, Pujol S, Heras M, Sionis A, Lozano M, Gonzalez J et al. Effects of helicobacter pylori eradication on platelet activation and disease recurrence in patients with acute coronary syndromes. *Blackwell synergy* 2004 Dec;9(6):681.